Drug Type Small molecule drug |
Synonyms Ervogastat/Clesacostat, PF 7055341, PF-05221304/PF-06865571 + [2] |
Target |
Action inhibitors |
Mechanism ACC inhibitors(Acetyl-CoA carboxylase inhibitors), DGAT2 inhibitors(Diacylglycerol O-acyltransferase 2 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 2 |
First Approval Date- |
RegulationFast Track (United States) |
Molecular FormulaC28H30N4O5 |
InChIKeyLXZMHBHEXAELHH-UHFFFAOYSA-N |
CAS Registry1370448-25-1 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Nonalcoholic Steatohepatitis | Phase 2 | Japan | 28 Jul 2020 |